Cancer News and Research

Latest Cancer News and Research

Experimental therapy uses immune system to boost cure rate in neuroblastoma

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

27 May 2009

1 million California residents travel to Mexico annually for health care, study finds

About one million adults living in California, including 500,000 immigrants, travel to Mexico for health care each year, according to a study published Tuesday in the journal Medical Care, the San Diego Union-Tribune reports.

27 May 2009

Discovery of genetic cause for primary biliary cirrhosis

Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.

27 May 2009

Research offers insight into why some prostate cancer returns

The majority of men who receive one of the standard treatments for localized prostate cancer - surgery or radiation therapy - have an excellent outcome.

27 May 2009

To spread, skin cancer attacks immune dendritic cells

Dendritic cells are the sentinels of the immune system. When they're alert and on guard, they will marshal the body's immunosoldiers, T cells, to battle at the sight of harmful pathogens. But some diseases, such as cancer, are able to escape their watchful eye. By knocking out or beguiling dendritic cells, they slip the defenses of the immune system and sack the unsuspecting body.

27 May 2009

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

Cohesin protein disrupts gene function in Cornelia deLange syndrome

An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromosomes together also plays an important role in regulating genes in humans.

26 May 2009

Predicting higher risk for prostate cancer diagnosis

High-grade prostatic intraepithelial neoplasia (HGPIN) carries a high predictive value for future diagnosis of prostate cancer.

26 May 2009

Activated stem cells in damaged lungs could be first step toward cancer

Stem cells that respond after a severe injury in the lungs of mice may be a source of rapidly dividing cells that lead to lung cancer, according to a team of American and British researchers.

26 May 2009

Some Black women with advanced breast cancer opt against treatment, study finds

A new study has found that some black women with advanced breast cancer declined treatment with chemotherapy or radiation, though researchers did not know the reason why so many of the women opted against treatment, HealthDay/Las Vegas NOW reports.

26 May 2009

Terminally ill patients and their physicians delay conversations about end-of-life choices, study finds

About half of terminally ill patients do not have discussions with their physicians regarding end-of-life choices, according to a Harvard Medical School study published in the Archives of Internal Medicine, the Boston Globe reports.

26 May 2009

Cancer drug capecitabine causes patient to lose fingerprints and be detained by U.S. immigration

Immigration officials held a cancer patient for four hours before they allowed him to enter the USA because one of his cancer drugs caused his fingerprints to disappear. His oncologist is now advising all cancer patients who are being treated with the commonly used drug, capecitabine, to carry a doctor's letter with them if they want to travel to the USA.

26 May 2009

Active ingredient in green tea shows promise in leukemia trials

Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

26 May 2009

Novel chemotherapy and biological agents brings dramatic increase in metastatic colon cancer survival

Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.

26 May 2009

Restricting carbohydrates may slow prostate tumor growth

Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center.

26 May 2009

Abraxane prolongs survival in metastatic breast cancer

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.

26 May 2009

Future cancer care, can we afford it?

When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment's medical benefits versus its possible side effects for the patient. Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient's welfare must also take into account the economic impact of the treatment on the patient and his or her family.

26 May 2009